Furio Gramatica

Furio Gramatica, physicist by training, is Director of Development & Innovation at Don Gnocchi Foundation, an Italian chain of healthcare and research centres specialized in post-acute medicine. In this role, he is responsible for the integration and translation of innovative solutions - from research and industry - into clinical practice and for developing alliances with relevant stakeholders in Europe. In the same organisation, he also managed medical technology research team and founded the Laboratory for Nanomedicine and Clinical Biophotonics. Formerly, he spent several years at CERN, Geneva, and in high-technology companies, with R&D and innovation management roles.  

Dr. Gramatica collaborates with companies and institutions in the field of medical technology and, for twenty years, has been collaborating as expert with the European Commission. He has an intense policy making activity, at European level, in healthcare technology products and services innovation and serving. 

His current main research interests are co-operation models among the stakeholders of the health technologies ecosystem (healthcare providers, SMEs, large industry, procurers, regulatory and reimbursement agencies, …) and the development of viable, real-world-data based metrics for an effective use of Value-Based Healthcare.

One of my great frustrations is to see start-ups fall at the final hurdle. Too many early-stage companies with promising innovations spend their energy – and funds – answering crucial questions about the safety and effectiveness of their products, only to find that they have no answers to the additional questions asked by payers. HTA bodies and procurement officers need to know the real-world impact of a new technology. How will it influence patient outcomes and experience? How will it change workflows and how clinicians spend their time? How will it shape the efficiency of the health system? If a researcher or entrepreneur cannot answer these questions, nobody cares how cool their gadget is. This is a tragedy. Great ideas wither and die; innovators flee for the US or Asia. From a European perspective, I see it as a waste of intellectual energy and potential innovation that could add much-needed value. I don’t blame the start-ups. They are working within an outdated framework that tells them their technologies are ‘mature’ when they reach what’s known as Technology Readiness Level 9 (TRL9) – a commonly used conceptualization of the path from idea to market. But, in reality, the road to TRL 9 ends before the widespread adoption of a medical technology. TRL 9 is not the destination; it’s just the end of the beginning. Introducing the iLoop It is time for a rethink. Looking at the bottlenecks facing late-stage research groups and early-stage companies, I believe the solution is to marry the development of evidence supporting CE marking with the generation of real-world evidence demanded by payers. That’s where the Innovation Loop (iLoop) comes in. When companies begin testing their prototypes, they should also measure the impact of their technology on the healthcare organisation; its usability and acceptance; and its sustainability...